04.06.21

ForeseeHome AMD Home Monitoring Real-World Data Analysis Demonstrates Substantial Benefit for Patients’ Vision

Source: ForeseeHome

03.31.21

Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Study for Lytenava

Source: Outlook Therapeutics

03.18.21

After the American Academy of Ophthalmology’s Urging, Blue Cross Blue Shield Clarifies Eylea Policy

Source: American Academy of Ophthalmology

03.09.21

Adverum Announces Shortened Timelines and Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMD

Source: Adverum Biotechnologies

03.09.21

Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial

Source: Graybug Vision

03.08.21

Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients

Source: Alteogen

03.02.21

Clearside Biomedical Completes Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMD

Source: Clearside Biomedical

02.23.21

Asclepix Therapeutics Partners With Notal Vision on Home OCT Remote Monitoring in DME and AMD Clinical Trials

Source: Asclepix Therapeutics

02.16.21

Kodiak Sciences Announces 1-Year Data from Ongoing Phase 1b Study of KSI-301 in Patients with Retinal Vascular Diseases

Source: Kodiak Sciences

02.16.21

Regenxbio Announces Additional Positive Interim Phase 1/2a and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD

Source: Regenxbio

View more stories